Will These Analyst Downgrades Hurt Thoratec (THOR) Stock Today?

NEW YORK (TheStreet) -- Thoratec  (THOR) received a pair of analyst downgrades on Thursday in the wake of the company's second-quarter earnings results.

Goldman Sachs downgraded the stock to "neutral" and set a $28 price target, as the company has limited visibility.

Credit Suisse downgraded Thoratec to "neutral" from "outperform" and set a $27 price target, as the company lowered its guidance meaningfully.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 26.13% to $24.06 in pre-market trading on Thursday.

-------------

Separately, TheStreet Ratings team rates THORATEC CORP as a "buy" with a ratings score of B-. TheStreet Ratings Team has this to say about their recommendation:

"We rate THORATEC CORP (THOR) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself."

You can view the full analysis from the report here: THOR Ratings Report

THOR ChartTHOR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Thor Industries Stock Drops Double Digits on Mixed Earnings

Oil, Yellen and World GDP Growth: How to Trade the Week Ahead

HeartWare Falters After Announcing Valtech Cardio Acquisition

Thoratec (THOR) Moving On Heavy Volume In The Pre-Market Hours

Thoratec Sale May Be Precursor of More Cardiac Industry M&A